Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Journal: Lancet (London, England)
Published: November 03, 2021
Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE Study.
Journal: Rheumatology and therapy
Published: June 03, 2021
Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR.
Journal: Drug safety
Published: March 19, 2021
Comment on "Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics".
Journal: Journal of the American Academy of Dermatology
Published: March 14, 2019
Phase 2a, randomized, double-blind, placebo-controlled, multicentre, parallel-group study of an H4 R-antagonist (JNJ-39758979) in adults with uncontrolled asthma.
Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
Published: December 12, 2017
Risk of malignancies associated with ustekinumab.
Journal: The British journal of dermatology
Published: September 24, 2017
Toreforant, A Histamine H4 Receptor Antagonist, in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results of 2 Phase II Studies.
Journal: The Journal of rheumatology
Published: May 20, 2016
A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate.
Journal: Annals of the rheumatic diseases
Published: May 03, 2016
Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy.
Journal: The Journal of rheumatology
Published: June 11, 2015
The histamine H₄ receptor antagonist, JNJ 39758979, is effective in reducing histamine-induced pruritus in a randomized clinical study in healthy subjects.
Journal: The Journal of pharmacology and experimental therapeutics
Published: May 13, 2014
Last Updated: 09/26/2026